National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 13/11/2017
Rapid review completed 24/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by the HSE 29/11/2017
Pre-submission consultation with Applicant 18/06/2018
Current Status Awaiting Applicant submission